Resource Center for Translational Research in Oncology
Financial Contract: 46/11.05.2009 ; proiect ID 203 ; SMIS code 2733
Competition code: POSCCE-A2-O2.2.3-2008-3
Beneficiary: "Carol Davila" UNIVERSITY OF MEDICINE & PHARMACY, BUCURESTI
Project timeframe: 20 months
Starting Date: 11.05.2009
End Date: 15.03.2011
Informations for Romanian Authorities
POS CCE
Axa prioritara 2: Competitivitate prin Cercetare, Dezvoltare Tehnologica si Inovare
Domeniul de interventie: D2.2. Investitii in infrastructura de CDI si dezvoltarea capacitatii administrative
Operatiunea: 2.2.3. Dezvoltarea unor retele de centre C-D, coordonate la nivel national si racordate la
retele europene si internationale de profil (GRID, GEANT)
Pentru informatii detaliate despre celelalte programe cofinantate de Uniunea Europeana va invitam sa
vizitati www.fonduri-ue.ro
Continutul acestui material nu reprezinta in mod obligatoriu pozitia oficiala a Uniunii Europene
sau a Guvernului Romaniei
The aim of the project is to build a GRID resource center dedicated to Biomedical translational research. This center will provide the necessary infrastructure for a Virtual Organization (VO) for oncology research.
GRID-type connectivity is essential in order to allow Romanian researchers to access to bio-molecular databases and to include the local research into the global standardization efforts of these databases build from heterogeneous sources.
In Romania the translational oncology, that address now only "in vivo" and "in vitro" tests, is on the beginning era of "in silica" tests. This is why the development and migration of the bio-medical application on GRID-like infrastructure is just starting. This project aims to create a VO that will virtually connect the research centers from Clinica de Chirurgie Oncologică I a UMF, (funcţionând în Institutul oncologic “Prof. Dr. Al. Trestioreanu”).
An important objective of this virtual organization will be the national integration of as many research units in oncology for an overall increase of Romanian oncology research relevance.
Last, but not least, an important goal is the access of specialized medical personal to continuous education using original research results, case databases and clinical data via this portal.
Disclaimer: This site is intended for medical specialist usage and does not provide heath information or advice for the non-medical public. For any medical advice, please, consult your doctor.
This site is funded solely by "Carol Davila" Univeristy of Medicine, Bucharest from own budget with additional funding coming from EU within POSCCE-A2-O2.2.3-2008-3, contract number 46/11.05.2009.
The content of this material does not represent necessarily the official position of the European Union or Romanian Government.
There is no advertising and no relation with any commercial pharmaceutical entity. There is no personal data of any kind (medical or related) posted on this site.
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials - Lancet. 2010 Nov 20;376(9754):1713-4.
BACKGROUND: High-dose aspirin (≥500 mg daily) reduces long-term incidence of colorectal cancer, but adverse effects might limit its potential for long-term prevention. The long-term effectiveness of lower doses (75-300 mg daily) is unknown. We assessed the effects of aspirin on incidence and mortality due to colorectal cancer in relation to dose, duration of treatment, and site of tumour.
RESULTS: In the four trials of aspirin versus control (mean duration of scheduled treatment 6·0 years), 391 (2·8%) of 14 033 patients had colorectal cancer during a median follow-up of 18·3 years. Allocation to aspirin reduced the 20-year risk of colon cancer (incidence hazard ratio [HR] 0·76, 0·60-0·96, p=0·02; mortality HR 0·65, 0·48-0·88, p=0·005), but not rectal cancer (0·90, 0·63-1·30, p=0·58; 0·80, 0·50-1·28, p=0·35). Where subsite data were available, aspirin reduced risk of cancer of the proximal colon (0·45, 0·28-0·74, p=0·001; 0·34, 0·18-0·66, p=0·001), but not the distal colon (1·10, 0·73-1·64, p=0·66; 1·21, 0·66-2·24, p=0·54; for incidence difference p=0·04, for mortality difference p=0·01).